SARS-CoV-2 Omicron spike protein receptor-binding domain (Omicron S-RBD)

The SARS-CoV-2 Omicron spike protein receptor-binding domain (RBD) is a critical structural component of the B.1.1.529 variant of the SARS-CoV-2 virus, which is the causative agent of COVID-19 (PubMed: 35016195). This domain is located within the S1 subunit of the spike glycoprotein and functions by binding directly to the human Angiotensin-Converting Enzyme 2 (ACE2) receptor, a process that is essential for viral attachment and subsequent entry into host cells (UniProt: P0DTC2). The Omicron RBD is characterized by a high density of mutations—including N501Y, E484A, and K417N—that significantly increase its binding affinity for ACE2 while simultaneously facilitating evasion from neutralizing antibodies elicited by previous infections or early-generation vaccines (PubMed: 35016195, NIH). As a primary target for therapeutic development, the RBD is the focus of monoclonal antibody therapies and the design of variant-specific vaccine boosters (FDA). However, the rapid evolution of the Omicron lineage has led to the emergence of sub-variants that render many previously authorized monoclonal antibodies ineffective, presenting a major challenge for clinical management (CDC). Understanding the structural and functional landscape of the Omicron RBD is vital for the development of next-generation, broad-spectrum sarbecovirus therapeutics.

Other names

SARS-CoV-2 B.1.1.529 spike RBDOmicron receptor-binding domainSARS-CoV-2 Omicron S1 protein RBDSARS-CoV-2 Omicron S-RBD

Neutralization of viral entry by blocking the interaction between the spike protein receptor-binding domain and the host Angiotensin-Converting Enzyme 2 (ACE2) receptor (PubMed: 35016195).